# Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

> **NCT05074355** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT05074355
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074355, "Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05074355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*